1	Decreased brain pH correlated with progression of Alzheimer's disease
2	neuropathology: a systematic review and meta-analyses of postmortem studies
3	
4	Hideo Hagihara, Ph.D. ^{1*} and Tsuyoshi Miyakawa, Ph.D. ^{1*}
5	
6	¹ Division of Systems Medical Science, Center for Medical Science, Fujita Health University,
7	Toyoake, Japan
8	
9	*Correspondence:
10	Hideo Hagihara
11	Division of Systems Medical Science, Center for Medical Science, Fujita Health University, 1-98
12	Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.
13	Tel: +81-562-93-9383; Fax: +81-562-93-5382; E-mail: h-hagi@fujita-hu.ac.jp
14	ORCID ID: 0000-0001-9602-9518
15	Tsuyoshi Miyakawa
16	Division of Systems Medical Science, Center for Medical Science, Fujita Health University, 1-98
17	Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.
18	Tel: +81-562-93-9376; Fax: +81-562-93-5382; E-mail: miyakawa@fujita-hu.ac.jp
19	ORCID ID: 0000-0003-0137-8200

20 Abstract

29

21 Background: Altered brain energy metabolism is implicated in Alzheimer's disease (AD). Limited and 22 conflicting studies on brain pH changes, indicative of metabolic alterations associated with neural 23 activity, warrant a comprehensive investigation into their relevance in this neurodegenerative 24 condition. Furthermore, the relationship between these pH changes and established AD 25neuropathological evaluations, such as Braak staging, remains unexplored.

26 Methods: We conducted quantitative meta-analyses on postmortem brain and cerebrospinal fluid 27pH in patients with AD and non-AD controls, using publicly available demographic data. We 28 collected raw pH data from studies in the NCBI GEO, PubMed, and Google Scholar databases.

Results: Our analysis of 17 datasets (457 patients and 315 controls) using a random-effects model 30 showed a significant decrease in brain and cerebrospinal fluid pH in patients compared to controls (Hedges' g = -0.54, p < 0.0001). This decrease remained significant after considering postmortem 31 32 interval, age at death, and sex. Notably, pH levels were negatively correlated with Braak stage, 33 indicated by the random-effects model of correlation coefficients from 15 datasets (292 patients and 34 159 controls) (adjusted r = -0.26, p < 0.0001). Furthermore, brain pH enhanced the discriminative 35 power of the APOE ε 4 allele, the most prevalent risk gene for AD, in distinguishing patients from 36 controls in a meta-analysis of four combined datasets (95 patients and 87 controls).

37 Conclusions: The significant decrease in brain pH in AD underlines its potential role in disease progression and diagnosis. This decrease, potentially reflecting neural hyperexcitation, could 38 39 enhance our understanding of neurodegenerative pathology and aid in developing diagnostic 40 strategies.

41Key words: Alzheimer's disease, brain pH, Braak stage, systematic review, meta-analysis

42 Introduction

Alzheimer's disease (AD) is a prevalent neurodegenerative disease worldwide, posing one of the 43 most significant health burdens of the 21st century (Prince et al., 2015; Scheltens et al., 2016). 44 45 Genetic studies have demonstrated that AD has a high heritability, with multiple genetic factors 46 contributing to the disease. Over 50 risk loci have been associated with AD at a genome-wide 47significance level (Sims et al., 2020). Among them, point mutations leading to the ɛ4 allele of 48 apolipoprotein E (APOE) are known to be the most potent genetic risk factor for the common 49 sporadic and late-onset forms of AD, as well as influencing rarer familial and early-onset forms of 50 the disease (Saunders et al., 1993; Belloy et al., 2019; Sims et al., 2020; Serrano-Pozo et al., 2021). 51 While the APOE gene is suggested to have no association with disease progression (Wilkosz et al., 52 2010), many other factors can influence the development and progression of pathophysiological changes in the brains of individuals with AD. In particular, pH in the brain could be significant in 5354the pathophysiology of AD, as low pH has been reported to exacerbate the aggregation of the 55 amyloid- β peptide and hyperphosphorylation of Tau protein, key pathological hallmarks of the 56 disease (Atwood et al., 1998; Basurto-Islas et al., 2013; Decker et al., 2021). To date, studies of pH 57 changes in the brain of AD have been limited and the results are inconsistent. One postmortem 58study involving four available datasets has reported a decrease in brain and cerebrospinal fluid 59(CSF) pH in patients with AD compared to control subjects in each dataset (Decker et al., 2021). 60 The results of the magnetic resonance spectroscopy (MRS) studies were inconsistent: a decrease 61 (Lyros et al., 2020), no significant change (Mandal et al., 2012), and an increase (Mecheri et al., 62 1997; Rijpma et al., 2018) in pH have been observed in the hippocampus and other regions of the brain of patients with AD. Furthermore, no study has yet elucidated the relationship between brain 63

pH and the progression of AD, particularly in the context of Braak staging – a well-established
 neuropathological method for AD diagnosis based on neurofibrillary tangles (Braak and Braak,
 1991).

67

68 Decreased brain pH has been consistently suggested in schizophrenia and bipolar disorder by 69 meta-analysis of MRS and postmortem studies (Dogan et al., 2018; Hagihara et al., 2018; Pruett and 70Meador-Woodruff, 2020). We recently found similar phenomenon in major depressive disorder in a 71systematic review and meta-analysis of postmortem studies (Hagihara and Miyakawa, submitted). A 72 decrease in brain pH is suggested to be associated with an increase in lactate level under these 73 psychiatric disorders (Prabakaran et al., 2004; Stork and Renshaw, 2005; Halim et al., 2008), which 74could be due to metabolic changes resulting from mitochondrial dysfunction and/or increased 75 glycolysis due to neuronal hyperexcitation. An increase in brain (Mullins et al., 2018; Hirata et al., 76 2024) and CSF (Liguori et al., 2015, 2016) lactate levels has been observed in patients with AD 77 compared to control subjects, suggesting common metabolic alterations and neuronal 78 hyperexcitability across such psychiatric and neurodegenerative disorders.

79

In view of the limited studies and contradictory results regarding pH changes in AD, in this study we conducted a systematic review and quantitative meta-analyses of pH in the postmortem brain and CSF in patients with AD compared to non-AD control subjects, utilizing publicly available demographic data. Furthermore, we conducted meta-analyses to investigate the association between pH and disease progression assessed by the Braak staging and the discriminative ability of brain pH in distinguishing patients with AD from control subjects.

86

87 Methods

88 Ethics approval and consent to participate

89 This study was performed based on publicly available data and no separate ethical approval was

90 required.

91

92 Identification and selection of eligible datasets of postmortem brain and CSF pH

93 Datasets were selected based on the availability of raw pH data of individual subjects. We searched 94 the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database 95 (GEO), PubMed, and Google Scholar for studies reporting individual pH data with key words "Alzheimer's disease", "brain pH", "postmortem" and "Braak". The dataset searches followed the 96 97 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Page et al., 2021) 98 and were conducted on October 2023. The workflow of the selection of pH datasets is shown in Fig. 99 1. Articles were screened first based on their titles, followed by a subsequent evaluation of their 100 abstracts to determine eligibility for full-text review. For records identified in PubMed and Google 101 Scholar, inclusion criteria were of studies involving human AD versus non-AD control comparisons 102 (CON) using postmortem brain or CSF samples and the availability of full text and individual raw 103 data. To minimize the inclusion of overlapping samples across different studies, we attempted to 104 identify and remove duplicated samples from studies that used partially overlapping samples from 105the same source, and then combined the remaining data into a single dataset. If conditions other 106 than CON or AD were present within the study, they were excluded from the current analysis. We 107 also obtained the accompanying demographic information from the identified datasets (i.e.,

108	postmortem interval (PMI), age at death, sex, Braak stage, and APOE genotype). In the dataset of
109	Ueberham 2006, Braak stage labeled as V-VI was treated as 5.5. In the datasets that provided ABC
110	score, scores 1, 2, and 3 in category "B" (representing Braak stage) were treated as stages 1.5, 3.5,
111	and 5.5, respectively, as score 1 encompasses Braak stage I or II, score 2 corresponds to stage III or
112	IV, and score 3 to stages V or VI (Montine et al., 2012). A score of 0 indicates the absence of
113	neurofibrillary pathology. In the dataset of Gabitto 2023, age labeled as 90+ was considered as 90.

114

115 Data analysis

116 Effect size, measured by Hedges' g, and standard error was calculated within each dataset, and the 117random effects model was applied using the function metagen in the R package meta (version 6.5-0). Analysis of covariance (ANCOVA) were performed using the GLM procedure in SAS (version 118 119 3.81; SAS Institute Inc., Cary, NC, USA). For a correlation analysis, we calculated the Pearson 120 correlation coefficient within each dataset. To estimate the standard error of the correlation coefficient, we used the formula: $SE_r = (1-r^2)/(n-2)^{1/2}$, where r is the Pearson correlation coefficient, 121 122 and n is the number of samples in the correlation. We then applied the random effects model to the 123 correlation coefficient (r) and its standard error (SE_r), as described above. Z-score transformation, a 124method of data normalization for direct comparison between different conditions, was applied to 125 each pH value using individual subject data within each dataset according to the following formula: 126Z-score = $(value_P - mean value_{P1...Pn})/standard deviation_{P1...Pn}$, where P is any pH or lactate and 127 P1...Pn represent the aggregate measure of all pH values. We conducted the receiver operating 128characteristics (ROC) curve analysis to evaluate the discriminative ability of the APOEE4 status, pH 129 level, and their combination in identifying patients with AD from control subjects, as assessed by

130	the numerical gains in the area under the curve (AUC). The ROC analyses were performed using
131	GraphPad Prism 8 (version 8.4.2; GraphPad Software, San Diego, CA). For ROC analyses, z-score
132	transformation, a conventional method for data normalization to enable direct comparison between
133	different conditions, was applied to pH values within each dataset, given their heterogeneity across
134	datasets. Multiple logistic regression analyses were applied to the z-score of pH level, APOEE4
135	status (yes = 1, i.e. $\varepsilon 3/\varepsilon 4$ and $\varepsilon 4/\varepsilon 4$; no = 0), and their combination, respectively.
136	

137 Results

138 Search results

139Following screening the 250 and 67 records retrieved from the searches in PubMed and Google 140Scholar, and the NCBI GEO database, 20 and 4 studies were identified to report raw pH data, 141respectively (Fig. 1). After removing duplicates, a total of 19 datasets were processed for the 142meta-analysis: 1) 17 datasets for comparison analysis of pH between patients with AD and control 143subjects (Fig. 2); 2) 15 for correlation analysis between pH and Braak stage (Fig. 3); and 3) seven 144for comparison analysis of pH between APOEE4 carriers and non-APOEE4 carriers (Supplementary 145 Fig. 3) and ROC curve analysis (Fig. 4). A summary of the datasets, which contains information on 146pH, PMI, age at death, and sex, is presented in Supplementary Table 1. The source and references of 147the datasets used are also included in Supplementary Table 1. The raw data analyzed in this study 148are provided in Supplementary Table 2.

149

150 Decreased brain and CSF pH in AD

151 In the 17 datasets obtained (Supplementary Table 1), six showed a significant decrease in pH in

152patients with AD compared to the corresponding controls within each dataset (GSE44771, p = 3.51153 $\times 10^{-7}$; GSE84422, p = 0.044; Guennewig 2021, p = 0.0016; Haytural 2021, p = 0.015; Jacobs 2006, 154 p = 0.021; Passila 2019, 2020, p = 0.033; two-tailed unpaired t-test). The others showed no 155 significant difference in pH between patients and controls. No datasets showed a significant 156 increase in pH. Funnel plot and Egger's test showed no evidence of publication bias for the 17 157 datasets (t = -0.89, p = 0.39; Supplementary Fig. 1). The meta-analysis using the random effects 158 model revealed a significant decrease in pH in patients with AD compared control subjects (Hedges' g = -0.54, z = -4.97, p < 0.0001, 95% CI = [-0.75; -0.33]) (Fig. 2). The I^2 test showed high 159heterogeneity suggesting significant differences between datasets ($I^2 = 65\%$, p < 0.01). In a two-way 160 161 ANCOVA, with the dataset and diagnosis as the main factors, the effect of diagnosis remained 162 significant (mean square (MS) = 2.25, F = 23.78, p < 0.0001), while no significant effects were 163 observed for PMI (MS = 0.12, F = 1.24, p = 0.26), age at death (MS = 0.35, F = 3.71, p = 0.055), or sex (MS = 0.29, F = 3.06, p = 0.081). The effect of dataset was significant (MS = 1.31, F = 13.85, p164 165 < 0.0001). These results suggest that, while the pH varied between datasets, it was decreased in 166 patients with AD compared to controls, independently of the covariates examined.

167

168 A decrease in pH is associated with progressive brain pathological changes

The current assessment of the severity of pathological changes in AD is mainly based on the Braak staging, where stages I–II represent clinically silent cases, stages III–IV incipient AD, and stages V–VI fully developed AD (Braak and Braak, 1991). We then examined the relationship between brain pH levels and the Braak stage. In the 15 datasets obtained (Supplementary Table 1), four showed a significant negative correlation between pH levels and Braak stage in each dataset

(GSE84422, r = -0.24, p = 0.015; Passila 2019, 2020, r = -0.50, p = 0.018; Jacobs 2006, r = -0.49, p174175 = 0.0064; Haytural 2021, r = -0.64, p = 0.010). The others showed no significant correlation within 176 datasets. The meta-analysis, employing a random effects model, revealed a significant negative 177 correlation between pH levels and Braak stage (adjusted r = -0.26, p < 0.0001, 95% CI = [-0.38; 178 -0.13]) (Fig. 3). This negative correlation was corroborated by linear regression analysis on 15 179combined datasets, standardized using z-score normalization, which showed a modest but significant relationship (r = -0.20, $p = 1.37 \times 10^{-5}$; Supplementary Fig. 2). These results suggest that 180 181 lower pH levels are associated with higher severity of the disease.

182

The brain pH also showed significant negative correlations with other pathological and clinical rating scores, including clinical dementia rating (r = -0.22, p = 0.026), average neuritic plaque density (r = -0.25, p = 0.0095), sum of Consortium to Establish a Registry for Alzheimer's Disease (CERAD) rating scores in multiple brain regions (r = -0.34, p = 0.0004), and sum of neurofibrillary tangles density in multiple brain regions (r = -0.24, p = 0.014) (Supplementary Fig. 3). These results support the idea that lower pH levels are associated with higher severity of the disease.

189

190 Brain pH improves discriminative ability of APOE E4 status in AD

191 The $\varepsilon 4$ allele of apolipoprotein E (*APOE*) is the strongest genetic risk factor for sporadic AD 192 (Belloy et al., 2019). While *APOE* $\varepsilon 4$ status did not affect brain pH level either in patients with AD 193 or control subjects (Supplementary Fig. 4), it exhibited a significant discriminative ability in 194 identifying patients from controls, as determined by the ROC curve analysis using seven datasets 195 consisting of 264 subjects (Fig. 4, Supplementary Table 1). The ROC AUC values of the

196 single-predictor model were 0.66 for *APOE* ϵ 4 status (95% CI: 0.60–0.73, p < 0.0001) and 0.62 for 197 the pH level (95% CI: 0.55–0.69, p = 0.0008). When the pH level was added to the *APOE* ϵ 4 status, 198 the ROC AUC value increased to 0.72 (95% CI: 0.66–0.78, p < 0.0001; p for difference 0.0075) 199 (Fig. 4). The discriminative accuracy of *APOE* ϵ 4 status was improved by the combination with the 200 pH level, suggesting that these two variables have a complementary value.

201

202 Discussion

The present study suggested that brain pH is decreased in patients with AD compared to control subjects even when PMI, age, and sex were considered as potential confounding factors. We recently showed that a decrease in brain pH in AD can be estimated through the analysis of gene expression patterns (Hagihara et al., 2023), which aligns with the findings of this study. Furthermore, the increased levels of brain lactate in patients with AD provide additional support for the observed decrease in pH.

209

210 A decrease in brain pH has been linked to an increase in lactate levels in schizophrenia and bipolar 211 disorder (Prabakaran et al., 2004; Stork and Renshaw, 2005; Halim et al., 2008). An increase in 212 lactate levels is considered indicative of metabolic alterations resulting from mitochondrial 213 dysfunction and/or increased glycolysis due to neuronal hyperexcitation. Lactate is thought to be a 214 relatively strong acid due to its ability to almost completely dissociate into H^+ ions and lactate 215 anions at cellular pH (Siesjö, 1985). Indeed, hyperexcitation in certain neurons and/or neural 216 circuits has been suggested in the etiology of AD (Busche and Konnerth, 2016; Murano et al., 2019; 217 Maestú et al., 2021). Furthermore, an increase in brain (Mullins et al., 2018; Hirata et al., 2024) and

218 CSF (Liguori et al., 2015, 2016) lactate levels has been observed in patients with AD compared to 219 control subjects. Neuronal hyperexcitation (Palop et al., 2007; You et al., 2017) and increased brain 220 lactate and decreased brain pH levels (Hagihara et al., 2024) have been observed in a well-known 221 mouse model of AD harboring the human amyloid precursor protein (APP) mutant allele that is 222 linked to familial AD. At a cellular level, glycolysis and subsequent lactate release are stimulated by 223 the uptake of the neurotransmitter glutamate in astrocytes following neuronal activation, as 224 demonstrated in an in vitro study (Pellerin and Magistretti, 1994). Astrocytes are considered to 225 prefer lactate production in the brain. A shift towards excitation would increase energy demands in 226 neurons, potentially prompting astrocytes to elevate lactate production, which in turn could lower 227brain pH. Indeed, increased lactate levels, accompanied by astrocyte activation, have been observed 228 in the brains of individuals of AD (Hirata et al., 2024). Therefore, the observed decrease in brain pH 229 may be attributed to elevated lactate levels induced by neuronal hyperexcitation in AD. 230 Activity-dependent acidosis has been suggested to suppress neuronal activity in animal models of 231 neonatal febrile seizures and is proposed as an intrinsic mechanism for the self-termination of 232 seizures (Chesler and Kaila, 1992; Schuchmann et al., 2006; Pavlov et al., 2013). Further research is 233 needed to determine whether a decrease in brain pH is related to such compensatory mechanisms in 234chronic degenerative diseases.

235

We found a negative correlation between brain pH and Braak stage, suggesting a lower brain pH as the disease course progresses. Braak staging of AD is based on the propagation of tau neurofibrillary tangles in the brain and the stage of tau pathology is associated with cognitive impairment (Braak and Braak, 1991). It is hypothesized that soluble amyloid- β oligomers cause

11

240 hyperphosphorylation of tau and the accumulation of neurofibrillary tangle (Zheng et al., 2002); however, the local relationship between amyloid and tau was restricted in several brain regions 241 242 (Iaccarino et al., 2018), suggesting additional causes for tau accumulation. Interestingly, neuronal 243 hyperexcitation has been suggested to enhances tau protein translation in neurons, which may lead 244 to the pathological accumulation of tau in soma and dendrite of neuronal cells (Kobayashi et al., 245 2017, 2019). Therefore, a decrease in pH and the accumulation of tau may occur in parallel due to 246 neuronal hyperexcitation. Furthermore, acidic conditions could increase the abnormal 247 hyperphosphorylation of tau protein in vitro (Basurto-Islas et al., 2013). These potential direct and 248 indirect relationships between pH and tau pathology could contribute to the observed negative 249 correlation between pH and Braak stage. Brain pH may serve as a surrogate for Braak stage.

250

We found that brain pH significantly improved discriminative accuracy of *APOE*ɛ4 status in distinguishing patients with AD from control subjects. A previous *in vivo* MRS study showed that brain pH improved diagnostic accuracy of brain metabolite (i.e., N-acetylaspartate/creatine ratio) for AD (Lyros et al., 2020). While brain pH alone exhibited relatively low (AUC of 0.62 in this study) to moderate (AUC of 0.81 in (Lyros et al., 2020)) accuracy for distinguishing patients with AD from control subject, combining it – measured in CSF or by MRS – with other markers could be a valuable biological strategy to assist in the diagnosis of AD.

258

Regarding potential bias in this study, the Egger's regression test on the funnel plot showed no significant publication bias across datasets analyzed. Additionally, relying on demographic rather than primary outcome data may minimize typical outcome bias.

12

262

263 A significant limitation of this study may involve the lack of consideration for other potential 264 confounding factors affecting postmortem brain pH than age at death, PMI, and sex. Factors prior to 265 death, or agonal states, and the cause and manner of death can influence postmortem brain pH 266 through alterations in blood oxygenation, brain perfusion, and biochemical content (Lewis, 2002; 267 Tomita et al., 2004). If patients with AD experienced prolonged agonal conditions compared to 268 controls in the datasets used, we cannot rule out the possibility that the observed decrease in pH was 269 influenced by such factors. It is technically difficult to exclude the influence of potential 270 confounding factors in human studies. In this circumstance, studies in animal models can be useful 271alternatives to confirm whether changes in brain pH are involved in the pathophysiology of 272 neuropsychiatric disorders, as they are essentially exempt from such confounding factors. In our 273 recent study, we showed that APP transgenic AD model mice exhibited a decrease in brain pH 274 compared to corresponding control mice (Hagihara et al., 2024), supporting the notion that this 275 phenomenon is intrinsically related to pathophysiology of AD rather than mere an artifact.

276

In conclusion, this study suggested that postmortem brain and CSF pH is decreased in patients with AD compared to control subjects. The decrease in pH may occur independent of having $APOE\varepsilon 4$ genotype, the most prominent genetic risk of AD. Neuronal hyperexcitation may lead to the decrease in pH, which may be exacerbated in the disease course. It remains undetermined whether such a decrease in pH is associated with either beneficial or detrimental effects on psychiatric conditions, which is required to be addressed in the future studies.

283

13

284 Acknowledgements

285	The authors than	k Yoko Kagam	i and Harumi	Mitsuya fo	or their a	administrative	assistance.

286

287 Funding

- 288 This work was supported by MEXT Promotion of Distinctive Joint Research Center Program Grant
- Number JPMXP0618217663 and JSPS KAKENHI Grant Number JP20H00522.
- 290

291 Data availability

292 The raw data analyzed in this study are provided in Supplementary Table 2.

293

294 Author contributions

- 295 HH and TM conceived this study. HH performed data search, analyzed data, and drafted the
- 296 manuscript. All authors contributed to revising the manuscript and approved its final version.

297

298 **Conflict of Interest**

- 299 The authors have nothing to disclose.
- 300

301 Additional information

302 The review was not registered elsewhere. The review protocol was not prepared.

303 References

- Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi
 RE, Bush AI (1998) Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by
 Conditions Representing Physiological Acidosis. J Biol Chem 273:12817–12826.
- Basurto-Islas G, Grundke-Iqbal I, Tung YC, Liu F, Iqbal K (2013) Activation of Asparaginyl
 Endopeptidase Leads to Tau Hyperphosphorylation in Alzheimer Disease. J Biol Chem
 288:17495–17507.
- Belloy ME, Napolioni V, Greicius MD (2019) A Quarter Century of APOE and Alzheimer's
 Disease: Progress to Date and the Path Forward. Neuron 101:820–838.
- Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta
 Neuropathol (Berl) 82:239–259.
- Busche MA, Konnerth A (2016) Impairments of neural circuit function in Alzheimer's disease.
 Philos Trans R Soc B Biol Sci 371:20150429.
- 316 Chesler M, Kaila K (1992) Modulation of pH by neuronal activity. Trends Neurosci 15:396–402.
- Decker Y, Németh E, Schomburg R, Chemla A, Fülöp L, Menger MD, Liu Y, Fassbender K (2021)
 Decreased pH in the aging brain and Alzheimer's disease. Neurobiol Aging 101:40–49.
- Dogan AE, Yuksel C, Du F, Chouinard V-A, Öngür D (2018) Brain lactate and pH in schizophrenia
 and bipolar disorder: a systematic review of findings from magnetic resonance studies.
 Neuropsychopharmacology 43:1681–1690.
- Hagihara H et al. (2024) Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment. eLife 12:RP89376.
- Hagihara H, Catts VS, Katayama Y, Shoji H, Takagi T, Huang FL, Nakao A, Mori Y, Huang K-P,
 Ishii S, Graef IA, Nakayama KI, Shannon Weickert C, Miyakawa T (2018) Decreased brain
 pH as a shared endophenotype of psychiatric disorders. Neuropsychopharmacology
 43:459–468.

- Hagihara H, Murano T, Miyakawa T (2023) The gene expression patterns as surrogate indices of pH
 in the brain. Front Psychiatry 14:1151480.
- Halim ND, Lipska BK, Hyde TM, Deep-Soboslay A, Saylor EM, Herman M, Thakar J, Verma A,
 Kleinman JE (2008) Increased lactate levels and reduced pH in postmortem brains of
 schizophrenics: medication confounds. J Neurosci Methods 169:208–213.
- Hirata K et al. (2024) Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's
 Disease. Ann Neurol 95:104–115.
- Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, Gorno-Tempini ML, Janabi
 M, Kramer JH, Lazaris A, Lockhart SN, Miller BL, Miller ZA, O'Neil JP, Ossenkoppele R,
 Rosen HJ, Schonhaut DR, Jagust WJ, Rabinovici GD (2018) Local and distant relationships
 between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage Clin
 17:452–464.
- Kobayashi S, Tanaka T, Soeda Y, Almeida OFX, Takashima A (2017) Local Somatodendritic
 Translation and Hyperphosphorylation of Tau Protein Triggered by AMPA and NMDA
 Receptor Stimulation. eBioMedicine 20:120–126.
- Kobayashi S, Tanaka T, Soeda Y, Takashima A (2019) Enhanced Tau Protein Translation by
 Hyper-Excitation. Front Aging Neurosci 11:322.
- Lewis DA (2002) The Human Brain Revisited: Opportunities and Challenges in Postmortem
 Studies of Psychiatric Disorders. Neuropsychopharmacology 26:143–154.
- Liguori C, Chiaravalloti A, Sancesario G, Stefani A, Sancesario GM, Mercuri NB, Schillaci O,
 Pierantozzi M (2016) Cerebrospinal fluid lactate levels and brain [18F]FDG PET
 hypometabolism within the default mode network in Alzheimer's disease. Eur J Nucl Med
 Mol Imaging 43:2040–2049.
- Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG, Pierantozzi M (2015) CSF
 lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease. J
 Neurol Neurosurg Psychiatry 86:655–659.
- Lyros E, Ragoschke-Schumm A, Kostopoulos P, Sehr A, Backens M, Kalampokini S, Decker Y,

Lesmeister M, Liu Y, Reith W, Fassbender K (2020) Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine 1H-MR spectroscopy study. Neurobiol Aging 87:60–69.

- Maestú F, de Haan W, Busche MA, DeFelipe J (2021) Neuronal excitation/inhibition imbalance:
 core element of a translational perspective on Alzheimer pathophysiology. Ageing Res Rev
 69:101372.
- Mandal PK, Akolkar H, Tripathi M (2012) Mapping of hippocampal pH and neurochemicals from
 in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive
 impairment, and Alzheimer's disease. J Alzheimers Dis JAD 31 Suppl 3:S75-86.
- Mecheri G, Marie-Cardine M, Sappey-Marinier D, Bonmartin H, Albrand G, Ferry G,
 Coppard-Meyer N, Courpron P (1997) In vivo hippocampal (31)P NMR metabolites in
 Alzheimer's disease and ageing. Eur Psychiatry J Assoc Eur Psychiatr 12:140–148.
- Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP,
 Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV,
 Hyman BT (2012) National Institute on Aging–Alzheimer's Association guidelines for the
 neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol
 (Berl) 123:1–11.
- Mullins R, Reiter D, Kapogiannis D (2018) Magnetic resonance spectroscopy reveals abnormalities
 of glucose metabolism in the Alzheimer's brain. Ann Clin Transl Neurol 5:262–272.
- Murano T, Hagihara H, Tajinda K, Matsumoto M, Miyakawa T (2019) Transcriptomic immaturity
 inducible by neural hyperexcitation is shared by multiple neuropsychiatric disorders.
 Commun Biol 2:32.
- Page MJ et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic
 reviews. Int J Surg 88:105906.
- Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A,
 Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and
 compensatory remodeling of inhibitory hippocampal circuits in mouse models of
 Alzheimer's disease. Neuron 55:697–711.

- Pavlov I, Kaila K, Kullmann DM, Miles R (2013) Cortical inhibition, pH and cell excitability in
 epilepsy: what are optimal targets for antiepileptic interventions?: Cortical inhibition, pH
 and cell excitability in epilepsy. J Physiol 591:765–774.
- Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a
 mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci
 91:10625–10629.
- Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT-J, Griffin JL, Wayland M, Freeman T,
 Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH,
 Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia:
 evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry
 9:684–697.
- Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M (2015) World Alzheimer Report 2015.
 The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.
 Alzheimer's Dis Int hal-03495438.
- Pruett BS, Meador-Woodruff JH (2020) Evidence for altered energy metabolism, increased lactate,
 and decreased pH in schizophrenia brain: A focused review and meta-analysis of human
 postmortem and magnetic resonance spectroscopy studies. Schizophr Res 223:29–42.
- Rijpma A, van der Graaf M, Meulenbroek O, Olde Rikkert MGM, Heerschap A (2018) Altered
 brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional 31P
 MR spectroscopic imaging study. NeuroImage Clin 18:254–261.

Saunders AM, Roses AD, Pericak-Vance MA, Dole KC, Strittmatter WJ, Schmechel DE,
Szymanski MH, McCown N, Manwaring MG, Schmader K, Breitner JCS, Goldgaber D,
Benson MD, Goldfarb L, Brown WT (1993) Apolipoprotein E ∈4 allele distributions in
late-onset Alzheimer's disease and in other amyloid-forming diseases. The Lancet
342:710–711.

- Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM
 (2016) Alzheimer's disease. The Lancet 388:505–517.
- 411 Schuchmann S, Schmitz D, Rivera C, Vanhatalo S, Salmen B, Mackie K, Sipilä ST, Voipio J, Kaila

412	K (2006)	Experimental	febrile	seizures	are	precipitated	by	a	hyperthermia-induced
413	respiratory	alkalosis. Nat l	Med 12:	817-823.					

- Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer's disease: advances in genetics,
 pathophysiology, and therapeutic approaches. Lancet Neurol 20:68–80.
- Siesjö BK (1985) Acid-Base Homeostasis in the Brain: Physiology, Chemistry, and Neurochemical
 Pathology. In: Progress in Brain Research (K. Kogure K-AH BK Siesjö and FA Welsh, ed),
 pp 121–154 Molecular Mechanisms of Ischemic Brain Damage. Elsevier.
- Sims R, Hill M, Williams J (2020) The multiplex model of the genetics of Alzheimer's disease. Nat
 Neurosci 23:311–322.
- 421 Stork C, Renshaw PF (2005) Mitochondrial dysfunction in bipolar disorder: evidence from
 422 magnetic resonance spectroscopy research. Mol Psychiatry 10:900–919.
- Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, Overman KM, Atz ME, Myers RM,
 Jones EG, Watson SJ, Akil H, Bunney Jr. WE (2004) Effect of agonal and postmortem
 factors on gene expression profile: quality control in microarray analyses of postmortem
 human brain. Biol Psychiatry 55:346–352.
- Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, Sweet RA (2010)
 Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 22:281–290.
- You JC, Muralidharan K, Park JW, Petrof I, Pyfer MS, Corbett BF, LaFrancois JJ, Zheng Y, Zhang
 X, Mohila CA, Yoshor D, Rissman RA, Nestler EJ, Scharfman HE, Chin J (2017)
 Epigenetic suppression of hippocampal calbindin-D28k by ΔFosB drives seizure-related
 cognitive deficits. Nat Med 23:1377–1383.
- Zheng W-H, Bastianetto S, Mennicken F, Ma W, Kar S (2002) Amyloid β peptide induces tau
 phosphorylation and loss of cholinergic neurons in rat primary septal cultures.
 Neuroscience 115:201–211.
- 436

437 Figure legends

438 Figure 1. Workflow of the selection of postmortem brain and CSF pH datasets.

439

440 Figure 2. Decreased pH in the postmortem brain and CSF of patients with AD. Forest plot of

- 441 meta-analysis comparing postmortem brain and CSF pH between patients with AD and non-AD
- 442 control subjects. 95% CI, 95% confidence interval; SE, standard error; SMD, standardized mean
- 443 difference.
- 444

```
445 Figure 3. Negative correlation between brain pH and Braak stages. Forest plot of meta-analysis
```

- 446 of correlation between brain pH and Braak stages. 95% CI, 95% confidence interval; CC,
- 447 correlation coefficient; SE, standard error.
- 448

449 Figure 4. Brain pH level increases discriminative accuracy of APOE a status for AD. ROC

- 450 curves for brain pH level, APOEE4 status, and their combination to assess the accuracy of prediction
- 451 of AD against controls. AUC, area under the curve.
- 452
- 453 Supplementary information
- 454 Supplementary Table 1. Summary of datasets used in this study
- 455
- 456 Supplementary Table 2. Raw data analyzed in this study
- 457
- 458 Supplementary Figure 1. Funnel plot of the included datasets. Each plot represents a dataset. SE,
- 459 standard error; SMD, standardized mean difference.

460

Supplementary Figure 2. Scatter plot depicting the negative correlation between pH (z-score) and Braak stages. A z-score was calculated for each subject within the dataset to standardize pH measurements. Each dot represents the data for an individual subject. *r*, Pearson correlation coefficient.

465

466 Supplementary Figure 3. Significant correlation between a decrease in brain pH and an 467 increase in disease severity. Data of GSE84422 was analyzed. Scatter plot of correlation between 468 brain pH and clinical dementia rating (A), average neuritic plaque density (B), sum of Consortium 469 to Establish a Registry for Alzheimer's Disease (CERAD) rating scores in multiple brain regions (C), 470 and sum of neurofibrillary tangles density in multiple brain regions (D). The solid line indicates the 471 regression line, and the dashed line indicates the 95% confidence interval. *r*, Pearson correlation 472 coefficient.

473

Supplementary Figure 4. No significant effect of *APOE* ε 4 status on brain pH. Forest plot of meta-analysis comparing postmortem brain pH between *APOE* ε 4 carriers and non-carriers in control subjects (A; Hedges' g = -0.40, 95% CI = [-0.80; 0.0056], p = 0.053) and patients with AD (B; Hedges' g = 0.046, 95% CI = [-0.31; 0.40], p = 0.80). 95% CI, 95% confidence interval; SE, standard error; SMD, standardized mean difference.





Dataset	Correlation coefficient	SE	Weight	Correlation coefficient, [95% CI]	Correlation coefficient, Random, 95% Cl
Haytural 2021	-0.6404	0.1636	8.1%	-0.64 [-0.96; -0.32]	—
Passila 2019, 2020	-0.4987	0.1680	7.8%	-0.50 [-0.83; -0.17]	
Jacobs 2006	-0.4865	0.1443	9.1%	-0.49 [-0.77; -0.20]	
Paasila 2021	-0.4581	0.2634	4.5%	-0.46 [-0.97; 0.06]	
Wong 2012	-0.4197	0.2605	4.5%	-0.42 [-0.93; 0.09]	
Ueberham 2006	-0.3500	0.3103	3.5%	-0.35 [-0.96; 0.26]	
Tzioras 2019	-0.3328	0.1744	7.5%	-0.33 [-0.67; 0.01]	
GSE84422	-0.2351	0.0922	12.2%	-0.24 [-0.42; -0.05]	
Garamszegi 2023	-0.2325	0.4730	1.7%	-0.23 [-1.16; 0.69]	
Bayer 2009, 2014, Coulson 2010, Quinn 2012	-0.1676	0.1805	7.3%	-0.17 [-0.52; 0.19]	
Barrachina 2006	-0.1440	0.2190	5.8%	-0.14 [-0.57; 0.29]	
Colom-Cadena 2023	-0.0783	0.1571	8.4%	-0.08 [-0.39; 0.23]	
Gabitto 2023	0.0465	0.1102	11.1%	0.05 [-0.17; 0.26]	
Griswold 2021	0.0742	0.3315	3.1%	0.07 [-0.58; 0.72]	
GSE222007	0.1473	0.2306	5.4%	0.15 [-0.30; 0.60]	
Total (95% CI) Heterogeneity: Tau ² = 0.0266; Chi ² = 24.74, df = 1	4 (P = 0.04); l ²	² = 43%	100.0%	-0.26 [-0.38; -0.13]	· · · · · · · · · · · · · · · · · · ·
.	,				-1 -0.5 0 0.5 1
					Negative Positive
					correlation correlation



- *APOE*ε4 (AUC = 0.66, *p* < 0.0001)
 pH (AUC = 0.62, *p* = 0.0008)
- $APOE_{\epsilon}4 + pH (AUC = 0.72, p < 0.0001)$